Shots:
- The US FDA has approved Yuflyma, a biosimilar version of Humira (adalimumab) & its unbranded version for the treatment of HS in adolescents (≥12yrs.), & uveitis in children (≥2yrs.)
- Yuflyma, an anti-TNFα mAb, was previously approved by the FDA for rheumatoid & psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, & plaque psoriasis, as well as for adults with HS & uveitis
- Yuflyma (interchangeable biosimilar) was launched in the US in Jul 2023 & is available in prefilled syringes (20mg/0.2mL, 40mg/0.4mL & 80mg/0.8mL) & autoinjectors (40mg/0.4mL & 80mg/0.8mL)
Ref: Celltrion | Image: Celltrion| Press Release
Related News:- Celltrion’s Eydenzelt (Biosimilar, Eylea) Receives the US FDA’s Approval to Treat Multiple Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
